Together, these results show that HAPLN1-PTR1 signals through a novel CH60-TLR4 cell surface complex to activate pathobiological NF-κB signaling and mediate drug resistance in MM cells. This evidence concerns the gene HAPLN1 and Miyoshi myopathy.